Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Caille

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
The Journal of Pharmacology and Experimental Therapeutics|June 5, 2004
SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profileN Aubin, P Barneoud, C Carter, et al.
Cell Communication & Adhesion|June 18, 2002
Cx36 and the function of endocrine pancreasA Calabrese, M Güldenagel, A Charollais, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 19, 2003
SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessationC Cohen, O E Bergis, F Galli, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
The Journal of Pharmacology and Experimental Therapeutics|June 5, 2004
SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profileN Aubin, P Barneoud, C Carter, et al.
Cell Communication & Adhesion|June 18, 2002
Cx36 and the function of endocrine pancreasA Calabrese, M Güldenagel, A Charollais, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 19, 2003
SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessationC Cohen, O E Bergis, F Galli, et al.
Pageof 3